More News

Want to Read Locked Articles?

Already Have an Account?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Topics of Interest

Select one or more

Cataract
Refractive
Glaucoma
Retina
Diagnostics
Pharmaceuticals
Surgical Devices
Dry Eye
Cornea
Other
No elements found. Consider changing the search query.
List is empty.

Products of Interest

Select one or more

Comprehensive Report
Quarterly Update
Newsletter
Custom Research
Other
No elements found. Consider changing the search query.
List is empty.

Market Scope

13421 Manchester Road, Suite 101 | St. Louis, MO 63131 | Phone: 314-835-0600 | Email: info@market-scope.com

Careers at Market Scope | Privacy Policy

Harrow Health CEO Mark Baum Describes ‘Miracle’ Jury Verdict, His Focus on Changing Business Model

Author: Joan McKenna

Harrow Health CEO Mark Baum says he is grateful for a jury verdict requiring his company to pay Allergan only $48,500. Baum, speaking by phone May 20, said he views Allergan’s lengthy legal challenge against Harrow as an attempt to put the San Diego-based company out of business at a time when it is seeing record sales of its ophthalmic compounded drugs. Allergan, which sells US FDA approved ophthalmic drugs, including the dry eye drug Restasis, filed suit in 2017 against Imprimis Pharmaceuti...

Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.

Ophthalmic Market Perspectives Monthly Newsletter

6/25/2019

This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.